PPARs: Protectors or Opponents of Myocardial Function?
PPARs: Protectors or Opponents of Myocardial Function?
复制标题
DOI：
10.1155/2015/835985
复制
发表时间：
2015
期刊：
影响因子：
2.9
通讯作者：
Drosatos K
中科院分区：
文献类型：
--
作者：
Pol CJ;Lieu M;Drosatos K
美国有超过500万人患有心力衰竭（HF）并发症，这是一种迅速蔓延的健康并发症。导致心力衰竭的疾病包括缺血性心脏病、心肌病和高血压。过氧化物酶体增殖物激活受体（PPARs）是核受体家族的成员。PPAR有三种亚型：PPARα、PPARγ和PPARδ。它们可被内源性配体（如脂肪酸）以及药物激活。PPAR激活剂用于治疗几种代谢并发症，如与心力衰竭直接或间接相关的糖尿病和高脂血症。然而，其中一些药物有损害心脏功能的不良反应。这篇综述文章旨在总结当前关于PPAR生物学对心肌功能有益或有害影响的基础和临床研究结果。
Over 5 million people in the United States suffer from the complications of heart failure (HF), which is a rapidly expanding health complication. Disorders that contribute to HF include ischemic cardiac disease, cardiomyopathies, and hypertension. Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor family. There are three PPAR isoforms: PPARα, PPARγ, and PPARδ. They can be activated by endogenous ligands, such as fatty acids, as well as by pharmacologic agents. Activators of PPARs are used for treating several metabolic complications, such as diabetes and hyperlipidemia that are directly or indirectly associated with HF. However, some of these drugs have adverse effects that compromise cardiac function. This review article aims to summarize the current basic and clinical research findings of the beneficial or detrimental effects of PPAR biology on myocardial function.
影响因子：
4.6
作者：
Jarr KU;Eschricht S;Burkly LC;Preusch M;Katus HA;Frey N;Chorianopoulos E
通讯作者：
Chorianopoulos E